Livagen
Research OnlyAlso known as: KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.
Research Statistics
Russian bioregulator with exclusively Khavinson institute research; no independent Western replication and chromatin-binding mechanism remains theoretical.
Research Dossier
Overview
What is Livagen and what does the research say?
Mechanism of Action
The proposed mechanisms of Livagen are based entirely on Russian bioregulator research. No independent Western validation or human mechanistic data from controlled trials exists.
How It Works (Simplified)
Livagen targets liver function through gene expression modulation and related pathways:
Claimed to interact with DNA in hepatocytes, modulating expression of genes involved in liver function and regeneration.
Proposed to decondense heterochromatin in liver cells, potentially reactivating genes that become silenced with age or damage.
Cell culture studies suggest protection of hepatocytes from toxic insults, though mechanism is not fully characterized.
Russian studies suggest upregulation of hepatic antioxidant defenses, reducing oxidative damage in liver tissue.
Scientific Pathways
Hepatic Gene Expression Pathway (Proposed)
Livagen (KED) → DNA/Histone Interactions → Hepatocyte Gene Modulation
↓
Upregulation of Liver-Specific Proteins
↓
Enhanced Hepatocyte Function & RegenerationChromatin Remodeling Pathway (Proposed)
Livagen → Histone Interactions → Heterochromatin Decondensation in Hepatocytes
↓
Reactivation of Age-Silenced Hepatic GenesNote: These pathways are based on Russian bioregulator theory. The specific molecular targets and mechanisms have not been independently validated.
Important Limitations
- 100% of research from Russian institutions (primarily St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any findings
- No controlled human clinical trials have been conducted
- Specific molecular targets and binding sites not characterized
- Pharmacokinetics, bioavailability, and metabolism in humans unknown
- Translation from cell culture to human liver benefits is unconfirmed
- Regulatory status: Not approved anywhere; research compound only
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial effects on hepatic gene expression may begin. Cell culture studies suggest gene modulation occurs within days of treatment. No human pharmacokinetic data available.
Continued treatment in animal models shows progressive hepatoprotective effects. Chromatin remodeling and epigenetic changes may develop in liver tissue. Russian protocols typically involve treatment courses of several weeks.
Extended treatment periods in animal studies associated with improved liver function markers. Russian protocols often involve cyclical treatment patterns. Human response timeline is unknown.
Long-term effects are extrapolated from animal studies. Russian bioregulator protocols typically recommend cyclical treatment courses. Human pharmacokinetics, optimal duration, and long-term effects are completely uncharacterized.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Livagen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Livagen with other peptides. Based on published research and mechanistic considerations.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets - epithalon for telomerase/pineal, Livagen for hepatic gene expression. No known direct interactions.
Vilon
CompatibleBoth short peptide bioregulators from Russian research - Vilon targets thymus/immune function, Livagen targets liver. May be used in combination protocols.
Thymalin
CompatibleBoth Russian bioregulator peptides - thymalin for immune modulation, Livagen for hepatic support. Different tissue targets suggest compatibility.
BPC-157
CompatibleDifferent mechanisms for tissue support - BPC-157 broadly cytoprotective, Livagen specifically hepatic-focused. No known contraindications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Livagen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.